Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims
HC Wainwright initiated coverage on Gracell Biotechnologies Inc (NASDAQ:GRCL) with a Buy rating and a price target of $6. The China-based company…
Omega Therapeutics Could Offer ‘Intriguing’ Liver Cancer Drug, Analyst Says
HC Wainwright has initiated coverage on Omega Therapeutics Inc (NASDAQ:OMGA) with a Buy rating and a price target of $11. The analyst…
DigitalOcean’s 30%-Plus Revenue Growth & 20% FCF Margin Attainable In CY24, Analyst Says
Needham analyst Mike Cikos initiates coverage on DigitalOcean Holdings Inc (NYSE:DOCN) with a Buy rating and a price target of $36. Cikos…
Why This Shopify Analyst Says It’s Time To Sell The E-Commerce Stock
In October, Shopify Inc (NYSE: SHOP) reported an earnings beat for the third quarter.
Yet there is near-term risk to the company’s revenues and long-term risk to its profitability, according to UBS.
Citigroup Initiates Coverage On General Dynamics with Buy Rating, Announces Price Target of $298
Citigroup analyst Jason Gursky initiates coverage on General Dynamics (NYSE:GD) with a Buy rating and announces Price Target of $298.
B of A Securities Reinstates Underperform on Altice USA, Announces $3.5 Price Target
B of A Securities analyst Jessica Reif Cohen reinstates Altice USA (NYSE:ATUS) with a Underperform and announces $3.5 price target.
Lake Street Initiates Coverage On BARK with Buy Rating, Announces Price Target of $5
Lake Street analyst Ryan Meyers initiates coverage on BARK (NYSE:BARK) with a Buy rating and announces Price Target of $5.
Maxim Group Initiates Coverage On Blue Water Vaccines with Buy Rating, Announces Price Target of $4
Maxim Group analyst Jason McCarthy initiates coverage on Blue Water Vaccines (NASDAQ:BWV) with a Buy rating and announces Price Target of $4.
UBS Initiates Coverage On Shopify with Sell Rating, Announces Price Target of $30
UBS initiates coverage on Shopify (NYSE:SHOP) with a Sell rating and announces Price Target of $30.
UBS Initiates Coverage On Privia Health Group with Buy Rating, Announces Price Target of $30
UBS analyst Andrew Mok initiates coverage on Privia Health Group (NASDAQ:PRVA) with a Buy rating and announces Price Target of $30.